清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age

断裂(地质) 医学 地质学 古生物学
作者
Mark J Bolland,Zaynah Nisa,Anna Mellar,Chiara Gasteiger,Veronica Pinel,Borislav Mihov,Sonja Bastin,Andrew B. Grey,Ian R. Reid,Greg D. Gamble,Anne M. Horne
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:392 (3): 239-248 被引量:78
标识
DOI:10.1056/nejmoa2407031
摘要

BACKGROUND: Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate administration would prevent vertebral fractures in early postmenopausal women is unknown. METHODS: We conducted a 10-year, prospective, double-blind, randomized, placebo-controlled trial involving early postmenopausal women (50 to 60 years of age) with bone mineral density T scores lower than 0 and higher than -2.5 (scores of -1 or higher typically indicate normal bone mineral density) at the lumbar spine, femoral neck, or hip. Participants were randomly assigned to receive an infusion of zoledronate at a dose of 5 mg at baseline and at 5 years (zoledronate-zoledronate group), zoledronate at a dose of 5 mg at baseline and placebo at 5 years (zoledronate-placebo group), or placebo at both baseline and 5 years (placebo-placebo group). Spinal radiographs were obtained at baseline, 5 years, and 10 years. The primary end point was morphometric vertebral fracture, which was assessed semiquantitatively and defined as at least a 20% change in vertebral height from that seen on the baseline radiograph. Secondary end points were fragility fracture, any fracture, and major osteoporotic fracture. RESULTS: Of 1054 women with a mean age of 56.0 years at baseline, 1003 (95.2%) completed 10 years of follow-up. A new morphometric fracture occurred in 22 women (6.3%) in the zoledronate-zoledronate group, in 23 women (6.6%) in the zoledronate-placebo group, and in 39 women (11.1%) in the placebo-placebo group (relative risk, zoledronate-zoledronate vs. placebo-placebo, 0.56 [95% confidence interval {CI}, 0.34 to 0.92; P = 0.04]; and zoledronate-placebo vs. placebo-placebo, 0.59 [95% CI, 0.36 to 0.97; P = 0.08]). The relative risk of fragility fracture, any fracture, and major osteoporotic fracture was 0.72 (95% CI, 0.55 to 0.93), 0.70 (95% CI, 0.56 to 0.88), and 0.60 (95% CI, 0.42 to 0.86), respectively, when zoledronate-zoledronate was compared with placebo-placebo and 0.79 (95% CI, 0.61 to 1.02), 0.77 (95% CI, 0.62 to 0.97), and 0.71 (95% CI, 0.51 to 0.99), respectively, when zoledronate-placebo was compared with placebo-placebo. CONCLUSIONS: Ten years after trial initiation, zoledronate administered at baseline and 5 years was effective in preventing morphometric vertebral fracture in early postmenopausal women. (Funded by the Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12612000270819.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
10秒前
TingtingGZ完成签到,获得积分10
12秒前
TingtingGZ发布了新的文献求助10
16秒前
优美的烙完成签到,获得积分10
20秒前
21秒前
活力的尔蓉完成签到,获得积分10
27秒前
30秒前
37秒前
A29964095完成签到 ,获得积分10
37秒前
44秒前
喷火球发布了新的文献求助100
49秒前
开心的寄柔完成签到,获得积分10
51秒前
blenx完成签到,获得积分10
1分钟前
1分钟前
迷路万天完成签到,获得积分10
1分钟前
1分钟前
1分钟前
隐形忆丹完成签到,获得积分10
1分钟前
1分钟前
1分钟前
Jun的应助被JINX采纳,获得10
1分钟前
可靠的夕阳完成签到,获得积分10
1分钟前
ww发布了新的文献求助10
1分钟前
ww完成签到,获得积分10
2分钟前
Criminology34的应助被科研通管家采纳,获得10
2分钟前
Criminology34的应助被科研通管家采纳,获得10
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
Criminology34的应助被科研通管家采纳,获得10
2分钟前
精明魔镜完成签到,获得积分10
2分钟前
五月完成签到,获得积分10
2分钟前
2分钟前
2分钟前
善良凝荷完成签到,获得积分10
2分钟前
2分钟前
科研通AI6.3的应助被喷火球采纳,获得10
2分钟前
adgn发布了新的文献求助10
3分钟前
3分钟前
标致茈完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173161
求助须知:如何正确求助?哪些是违规求助? 9565558
关于积分的说明 21780458
捐赠科研通 7767231
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555697
邀请新用户注册赠送积分活动 2476682